Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.

Earnings